TL;DR
Researchers have identified a shared molecular signature between psoriasis and acute myocardial infarction (AMI), centered on immune-driven inflammation. By combining bioinformatics with mouse models and human tissue validation, the study highlights seven "hub genes"—including CXCL8 and IL1B—as potential diagnostic markers and suggests that simvastatin could serve as a dual-targeted therapeutic.
What Problem Does This Paper Address?
Psoriasis is widely known as a chronic inflammatory skin condition, but it is increasingly recognized as a systemic disease. Epidemiological data shows a significant, independent link between psoriasis and an increased risk of acute myocardial infarction (AMI), or heart attack.
Despite this clinical correlation, the "why" remains fuzzy. What are the shared pathogenic networks that connect a skin flare-up to a cardiac event? This paper aims to bridge that gap by identifying common differentially expressed genes (DEGs) and biological pathways that drive both conditions, potentially uncovering new ways to diagnose and treat patients suffering from this dangerous comorbidity.
Methods
The authors employed a multi-stage workflow combining "dry-lab" bioinformatics with "wet-lab" experimental validation:
- Bioinformatics Pipeline: They analyzed transcriptomic data from the Gene Expression Omnibus (GEO) to find overlapping DEGs between psoriasis and AMI. They used tools like CIBERSORT to profile immune cell infiltration and cytoHubba (within Cytoscape) to identify "hub genes"—the most highly connected and influential genes in the disease network.
- Network Analysis: They constructed Protein-Protein Interaction (PPI) and Transcription Factor (TF) regulatory networks to understand how these genes are controlled.
- Experimental Validation: To move beyond computer models, the team performed:
- ELISA to measure protein levels in human serum.
- Immunohistochemistry (IHC) and qPCR on skin lesions from psoriasis patients and heart tissue from a mouse model of myocardial infarction (MI).
- Molecular Docking: They used AutoDock Vina to simulate how well the common drug simvastatin binds to the identified hub proteins.
Datasets
The study utilized two primary public datasets from the GEO database:
- GSE161683: Gene expression profiles from lesional and non-lesional skin samples of 9 psoriasis patients.
- GSE66360: Transcriptomic data from circulating endothelial cells in 49 AMI patients and 50 healthy controls.
Key Insights and Ideas
- The Neutrophil Connection: Functional enrichment analysis (GO and KEGG) revealed that the shared genes are heavily involved in neutrophil chemotaxis and the IL-17 signaling pathway. This suggests that the "bridge" between the skin and heart is built on specific types of white blood cell recruitment and pro-inflammatory signaling.
- The Seven Hubs: Out of 37 overlapping genes, seven emerged as critical "hubs": SLPI, S100A9, IL1B, CYBB, CXCL8, S100A12, and CXCL1. These genes are consistently upregulated in both diseases.
- Diagnostic Potential: The researchers found that these hub genes have high diagnostic accuracy. Specifically, S100A12 and IL1B showed Area Under the Curve (AUC) values of 0.89 and 0.88, respectively, suggesting they could serve as reliable biomarkers for identifying AMI risk in inflammatory contexts.
- Simvastatin’s Hidden Talent: While simvastatin is a standard cholesterol-lowering statin, molecular docking showed it has high binding affinity for the hub proteins CXCL8, IL1B, S100A9, and S100A12. This suggests the drug might provide pleiotropic (multi-action) benefits by directly dampening the shared inflammatory pathways.
Key Results
- Human Validation: ELISA tests confirmed significantly higher serum levels of CXCL8, IL1B, S100A9, and S100A12 in AMI patients compared to healthy individuals.
- Mouse Model Dynamics: In MI-induced mice, CXCL8 and IL-1B expression increased progressively over 7 days, while S100A9 peaked early (day 3), providing a temporal map of how these genes respond to cardiac injury.
- Skin vs. Heart: IHC staining showed that the same proteins (CXCL8, IL-1B, S100A9, S100A12) were significantly more abundant in psoriasis skin lesions than in healthy skin, confirming the molecular overlap.
- Binding Affinity: Molecular docking scores for simvastatin against the hub targets ranged from -6.2 to -6.8 kcal/mol, indicating stable and potentially effective interactions.
Limitations and Future Work
The authors acknowledge several hurdles:
- Data Source: The study relies on publicly available datasets which can introduce batch effects and heterogeneity.
- Sample Size: The patient cohorts in the initial datasets were relatively small, necessitating larger-scale studies to confirm the generalizability of the findings.
- Mechanistic Depth: While molecular docking is a strong predictive tool, the study lacks in vitro or in vivo functional assays to prove that simvastatin actually inhibits these specific proteins in a living system.
- Future Direction: The next logical step is to conduct clinical trials or more complex animal studies to see if targeting these specific hub genes can simultaneously improve skin symptoms and reduce cardiovascular risk.
Summary updated